A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallelgroup, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimers Disease (The AMARANTH Study)
A study for patients with early Alzheimer's Disease using study drug AZD3293
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAP6613
U.S. Govt. ID: NCT02245737
Contact: Lawrence Honig: 212-305-9194 / lh456@columbia.edu
Additional Study Information: The purpose of this study is to see if the study drug AZD3293 is effective and safe in treating early Alzheimer's disease compared with a placebo. A placebo is a tablet containing no drug. This study will also measure the levels of AZD39293 and its metabolite in the blood and evaluate the relationship between drug levels, efficacy (how well it works) and safety.
This study is closed
Lawrence Honig, MD, PhD
Do You Qualify?
Do you have Alzheimer's Disease? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Lawrence Honig